Back to search results

A Study of Ifinatamab Deruxtecan for Esophageal Squamous Cell Carcinoma

This study is testing a drug called ifinatamab deruxtecan for people with advanced or metastatic esophageal squamous cell carcinoma (ESCC), a type of cancer in the esophagus. You might be able to join if your cancer has progressed after receiving platinum-based chemotherapy and an immune checkpoint inhibitor (a type of drug that helps your immune system fight cancer). Researchers want to see if ifinatamab deruxtecan helps people live longer compared to standard chemotherapy options like docetaxel, paclitaxel, or irinotecan hydrochloride. The study aims to enroll about 510 participants.

Study design
This is an interventional study comparing ifinatamab deruxtecan to standard chemotherapy options. It plans to enroll about 510 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from the start of the study until death, for up to approximately 54 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06644781

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Recruiting
PHASE3Ages 18+InterventionalTreatment
Daiichi Sankyo
~510 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Ifinatamab deruxtecanDocetaxelPaclitaxelIrinotecan hydrochloride (HCl)

At a glance

Recruiting sites
131 of 132 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS)
Measured over From the date of randomization to the date of death due to any cause, up to approximately 54 months

Conditions

Esophageal Squamous Cell Carcinoma

Explore related trials

Esophageal Squamous Cell Carcinoma

NCT06644781

Where you'd take part

This study runs at 132 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Aarhus University Hospital

    Arhus N, Denmarkno site contact published

    Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, Chinano site contact published

    Recruiting

  • Aichi Cancer Center

    Nagoya, Japanno site contact published

    Recruiting

  • Akershus Universitetssykehus Hf

    Lørenskog, Norwayno site contact published

    Recruiting

  • Altnagelvin Area Hospital

    Belfast, United Kingdomno site contact published

    Recruiting

  • Amsterdam UMC - location VUmc

    Amsterdam, Netherlandsno site contact published

    Recruiting

  • Antwerp University Hospital

    Edegem, Belgiumno site contact published

    Recruiting

  • Anyang Cancer Hospital

    Anyang, Chinano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Daiichi Sankyo Contact for Clinical Trial Information
[email protected]
9089926400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Overall Survival (OS)From the date of randomization to the date of death due to any cause, up to approximately 54 months

    Overall Survival (OS) is defined as the time interval from the date of randomization to the date of death due to any cause.